Kjibo Pharmaceuticals: The board of directors has approved a share buyback plan.

Koji Pharmaceuticals Announcement: The annual shareholders meeting held on May 22, 2026 approved the authorization for the company to repurchase shares. According to this authorization, the company may repurchase up to 10% of the total number of shares issued on the day the relevant resolution was passed, up to a maximum of 57,096,024 shares of the company's stock. This authorization is referred to as the "2026 Share Repurchase Authorization". The Board of Directors has approved a share repurchase plan: from June 25, 2026 until the close of the next annual shareholders meeting, in accordance with the "2026 Share Repurchase Authorization", the company will repurchase up to 30,124,699 shares of the company's stock on the open market, which represents approximately 5% of the total number of shares issued as of May 31, 2026. The funding for the share repurchase will come from non-IPO fundraising sources, including operating revenue, interest income, and various subsidies.